ClinicalTrials.gg
CompletedNCT05586971EURELIA2Updated Jul 22, 2025

Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

A Phase 3 interventional study of Tigulixostat and Allopurinol in Gout, Hyperuricemia and Gout Flare, sponsored by LG Chem. Completed at 279 sites in 21 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-07-22.

Sponsored by LG Chem · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,202
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Gout by LG Chem — none open to participants now, none under way, none of them phase 3. Gout · LG Chem.

Enrollment
Largest of 11
2,202 · median 37
Started
2023
with 1 other
Phase 3
2 of 11
none open now
Registered
9th of 11
by date

Among the 11 studies in Gout by LG Chem, this one has the largest enrollment, is one of 2 that started in 2023, is one of 2 in phase 3, and was the 9th registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

None of the 11 studies in Gout by LG Chem is open now. The open studies under Gout, anywhere →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Gout by LG Chem as a file.
02

Study summary

The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.

03

Conditions studied

  • Gout
  • Hyperuricemia
  • Gout Flare
  • Tophi

Browse trials for

Keywords

  • Gout
  • Hyperuricemia
  • Xanthine Oxidase Inhibitor
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between the ages of 18 85 years, inclusive.
  • Subjects with hyperuricemia and a history or presence of gout per American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2015 criteria.
  • Subjects who are currently on urate-lowering therapies (ULT) with an sUA level ≥6.0 mg/dL at screening (Visit 1); or subjects who are currently not on ULT with an sUA level ≥7.0 mg/dL at screening (Visit 1). Subjects currently on ULT will undergo washout and must have an sUA level ≥7.0 mg/dL at Visit 3 to be randomized and participate in the study.
  • Subjects with a ≤50 kg/m2 and estimated (eGFR) ≥30 mL/min/1.73 m2 at screening (Visit 1).

Exclusion criteria

Exclusion Criteria:

  • Subjects with secondary hyperuricemia and enzymatic defects.
  • Subjects experiencing an acute gout attack (intense pain, swelling, or/and tenderness in the joint area) within 2 weeks prior to screening (Visit 1).
  • Subjects who have received pegloticase to treat gout which has not responded to the usual treatments.
  • Subjects who have not been receiving stable doses of drugs known to affect sUA levels for the last 3 weeks prior to screening (Visit 1).
  • Subjects with a history of xanthinuria (elevated levels of xanthine in the urine).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,202 participants (actual)

Study arms

  • Experimental
    Tigulixostat 100mg

    Tigulixostat 100mg, Once a day (QD) for up to 12 months

    Drug: Tigulixostat

  • Experimental
    Tigulixostat 200mg

    Tigulixostat 200mg, Once a day (QD) for up to 12 months

    Drug: Tigulixostat

  • Experimental
    Tigulixostat 300mg

    Tigulixostat 300mg (100mg + 200mg), Once a day (QD) for up to 12 months

    Drug: Tigulixostat

  • Active comparator
    Titrated allopurinol (100-800mg)

    Allopurinol 100-800mg, three times a day (TID) for up to 12 months. The allopurinol dose will be increased in 100 mg increments up to 800mg.

    Drug: Allopurinol

  • Placebo comparator
    Placebo

    Placebo, three times a day (TID) for up to 6 months.

    Drug: Placebo

Interventions

  • Xanthine Oxidase Inhibitor

    Also known as: LC350189

  • Xanthine Oxidase Inhibitor

  • DrugPlacebo

    Matching placebo

06

What researchers measure

Primary outcomes

  1. The proportion of subjects with sUA levels <6.0 mg/dL sustained at months 4, 5, and 6

    Serum uric acid (sUA) level will be measured at Month 4,5, and 6

    Time frame: Up to Month 6

Secondary outcomes

  1. The proportion of subjects with sUA levels <5.0 mg/dL sustained at months 4, 5, and 6

    Serum uric acid (sUA) level will be measured at Month 4,5, and 6

    Time frame: Up to Month 6

  2. Proportion of subjects with at least one gout flare from Month 6 to Month 12.

    Gout flare (intense pain, swelling, or/and tenderness in the joint area) will be assessed from baseline up to 12 months

    Time frame: From Month 6 to Month 12

  3. Proportion of subjects with complete resolution of ≥1 target tophus by Month 12

    Tophi will be measured by independent central blind reader

    Time frame: Up to Month 12

  4. Incidence rate of adverse event

    Safety assessment

    Time frame: Up to Month 12

07

Study locations

279 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • Alliance for Multispecialty Research, LLC
    Daphne, Alabama 36526, United States
  • Alliance for Multispecialty Research, LLC
    Mobile, Alabama 36608, United States
  • Syed Research Consultants, LLC
    Muscle Shoals, Alabama 35661, United States
  • Syed Research Consultants, LLC
    Sheffield, Alabama 35660, United States
  • Arizona Research Clinic, PLLC
    Chandler, Arizona 85225, United States
  • Arizona Arthritis & Rheumatology Associates, P.C.
    Flagstaff, Arizona 86001, United States
  • Arizona Arthritis and Rheumatology Research PLLC
    Glendale, Arizona 85306, United States
  • Arizon Arthritis & Rheumatology Research, PLLC
    Mesa, Arizona 85210, United States
  • Desert Clinical Research/CCT Research
    Mesa, Arizona 85213, United States
  • Elite Clinical Studies, LLC
    Phoenix, Arizona 85018, United States
  • Fiel Family and Sports Medicine/CCT Research
    Tempe, Arizona 85283, United States
  • Lynn Institute of the Ozarks
    Little Rock, Arkansas 72204, United States
  • Velocity Clinical Research
    Banning, California 92220, United States
  • American Clinical Trials
    Buena Park, California 90620, United States
  • Shreenath Clinical Service
    Lakewood, California 90805, United States
  • Rancho Cucamonga Clinical Research
    Rancho Cucamonga, California 91730, United States
  • TriWest Research Associates
    San Diego, California 92108, United States
  • Rheumatology Center of San Diego
    San Diego, California 92128, United States
  • Arthritis & Rheumatic Disease Specialties
    Aventura, Florida 33180, United States
  • Clinical Research of West Florida, Inc.
    Clearwater, Florida 33765, United States
  • Herco Medical and Research Center, Inc
    Coral Gables, Florida 33134, United States
  • Nouvelle Clinical Research LLC
    Cutler Bay, Florida 33189, United States
  • Omega Research Debary, LLC
    DeBary, Florida 32713, United States
  • Alliance for Multispecialty Research, LLC
    Fort Myers, Florida 33912, United States
  • Direct Helpers Research Center
    Hialeah, Florida 33012, United States
  • Best Quality Research, Inc
    Hialeah, Florida 33016, United States
  • New Generation Of Medical Research, LLC
    Hialeah, Florida 33016, United States
  • Vital Pharma Research
    Hialeah, Florida 33016, United States
  • Accel Research Sites - Lakeland
    Lake Mary, Florida 32746, United States
  • Accel Research Sites - St. Petersburg- Largo
    Lake Mary, Florida 32746, United States
  • ARS-Matiland Clinical Research Unit
    Lake Mary, Florida 32746, United States
  • Homestead Associates in Research,Inc
    Miami, Florida 33032, United States
  • Allied Biomedical Research Institute
    Miami, Florida 33155, United States
  • D&H National Research Centers, Inc.
    Miami, Florida 33155, United States
  • Ivetmar Medical Group, LLC
    Miami, Florida 33155, United States
  • Care Research Center Inc
    Miami, Florida 33175, United States
  • Pharmax Research of South Florida, Inc
    Miami, Florida 33175, United States
  • Miami Dade Medical Research Institute, LLC
    Miami, Florida 33176, United States
  • Clinical Site Partners, LLC dba Flourish Research
    Miami, Florida 33186, United States
  • M&A Medical Centers and Research
    Miami, Florida 33186, United States
  • HMD Research LLC
    Orlando, Florida 32819, United States
  • IMA Clinical Research
    St. Petersburg, Florida 33709, United States
  • Adult Medicine of Lake County, Inc.
    Tampa, Florida 32757, United States
  • Research Institute of South Florida, Inc.
    Tampa, Florida 33173, United States
  • Clinical Research of West Florida, Inc.
    Tampa, Florida 33606, United States
  • Clinical Research Trials of Florida, Inc.
    Tampa, Florida 33607, United States
  • Nodal Medical Center
    Tampa, Florida 33607, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Clinical Site Partners LLC dba CSP Orlando
    Winter Park, Florida 32789, United States
  • Conquest Research
    Winter Park, Florida 32789, United States
  • Centricity Research
    Columbus, Georgia 31904, United States
  • Arthritis Center of North Georgia
    Gainesville, Georgia 30501, United States
  • Vista Clinical Research, LLC
    Newnan, Georgia 30265, United States
  • East West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Family Care Research, LLC
    Boise, Idaho 83713, United States
  • Alliance for Multispecialty Research, LLC
    Meridian, Idaho 83642, United States
  • IMA Research, Inc.
    Chicago, Illinois 60602, United States
  • Great Lakes Clinical Trials
    Chicago, Illinois 60640, United States
  • Healthcare Research Network II, LLC
    Flossmoor, Illinois 60422, United States
  • Clinical Investigation Specialists, Inc
    Gurnee, Illinois 60031, United States
  • MediSphere Medical Research Center, LLC
    Evansville, Indiana 47714, United States
  • American Health Network of Indiana, LLC
    Franklin, Indiana 46131, United States
  • American Health Network of Indiana LLC
    Muncie, Indiana 47304, United States
  • Integrated Clinical Trial Services Inc.
    West Des Moines, Iowa 50265, United States
  • Women's & Family Care LLC, dba GTC Research
    Shawnee Mission, Kansas 66218, United States
  • Alliance for Multispecialty Research, LLC
    Wichita, Kansas 67207, United States
  • Alliance for Multispecialty Research, LLC
    Lexington, Kentucky 40509, United States
  • Versailles Family Medicine
    Versailles, Kentucky 40383, United States
  • Clinical Trials Management, LLC
    Covington, Louisiana 70433, United States
  • Clinical Trials Management
    Metairie, Louisiana 70006, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • Elite Clinical Research, LLC
    Jackson, Mississippi 39202, United States
  • Olive Branch Family Medical Center
    Olive Branch, Mississippi 38654, United States
  • Practice Dr David Headley
    Port Gibson, Mississippi 39150, United States
  • Healthcare Research Network
    Hazelwood, Missouri 63042, United States
  • Alliance for Multispecialty Research, LLC
    Kansas City, Missouri 64114, United States
  • Clay-Platte Family Medicine Clinic
    Kansas City, Missouri 64151, United States
  • IMA Clinical Research
    St Louis, Missouri 63117, United States
  • St. Louis Medical Professionals, LLC
    St Louis, Missouri 63119, United States
  • Montana Medical Research, Inc.
    Missoula, Montana 59808, United States
  • Methodist Physicians Clinic/CCT Research
    Fremont, Nebraska 68025, United States
  • Meridian Clinical Research, LLC
    Norfolk, Nebraska 68701, United States
  • Healor Primary Care /CCT Research
    Las Vegas, Nevada 89102, United States
  • Wake Research - CRCN
    Las Vegas, Nevada 89118, United States
  • Alliance for Multispecialty Research, LLC.
    Las Vegas, Nevada 89119, United States
  • Albuquerque Center for Rheumatology
    Albuquerque, New Mexico 87102, United States
  • Inspire Santa Fe Medical Group
    Santa Fe, New Mexico 87505, United States
  • Long Island Regional Arthritis & Osteoporosis Care PC
    Babylon, New York 11702, United States
  • IMA Clinical Research
    New York, New York 10036, United States
  • Conquest Research
    Vestal, New York 13850, United States
  • Presbyterian Hospital
    Charlotte, North Carolina 28277, United States
  • Triad Clinical Trials, LLC
    Greensboro, North Carolina 27410, United States
  • Olympus Family Medicine
    Hendersonville, North Carolina 28792, United States
  • Burke Primary Care
    Morganton, North Carolina 28655, United States
  • Carolina Research Center, Inc.
    Shelby, North Carolina 28150, United States
  • Lillestol Research LLC
    Fargo, North Dakota 58104, United States
  • Trinity Health Center Medical Arts
    Minot, North Dakota 58701, United States
  • Arthritis Associates of Northwest Ohio Inc.
    Perrysburg, Ohio 43551, United States
  • STAT Research
    Vandalia, Ohio 45377, United States

Showing the first 100 of 279 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Saag KG, Dalbeth N, Hsu CY, Kuo CF, Nuki G, Perez-Ruiz F, White WB, Hariri A, Lee Y, Jang Y, Han S, Choi HK. Evaluation of the efficacy and safety of a novel xanthine oxidase inhibitor, tigulixostat, in gout patients with hyperuricemia: Design of the EURELIA 1 and EURELIA 2 studies. Contemp Clin Trials. 2025 Apr;151:107843. doi: 10.1016/j.cct.2025.107843. Epub 2025 Feb 8. PubMed 39929260 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in May 2025, 25 months.

Of 21 phase 3 interventional studies under Gout, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 25. This study's 25 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2022
First posted
Oct 19, 2022
StartActual
Mar 30, 2023
Primary completionActual
May 6, 2025
CompletionActual
May 6, 2025
Last update
Jul 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05586971
Lead sponsor
LG Chem
Responsible party
Sponsor
First posted
Oct 19, 2022
Start date
Mar 30, 2023
Primary completion
May 6, 2025
Completion
May 6, 2025
Last update
Jul 22, 2025

Study contacts

Hyungjin Cho, MD
study director · LG Chem

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tigulixostat

Start the discussion